ASCO GU 2026: Intensifying Neoadjuvant Androgen Blockade Before Prostatectomy in High-Risk Prostate Cancer

Can intensified neoadjuvant hormonal therapy improve surgical outcomes in unfavorable intermediate- and high-risk localized prostate cancer? Fernando de Moura, Clinical Oncologist, Beneficência Portuguesa de São Paulo, presents results from the COACTION trial, a randomized, three-arm study evaluating darolutamide plus leuprorelin versus monotherapy prior to radical prostatectomy. The study explores whether combination androgen pathway inhibition can increase complete or minimal residual disease rates and potentially reshape the role of surgery in higher-risk disease.